At step 3, in those at very high risk, 62.6% (n = 46) of patients without ASCVD would be treated with high-intensity statins, ezetimibe, and a PCSK9 inhibitor (Fig. 2c). The gene discussed is PCSK9; the disease is atherosclerosis.